Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of large-fraction radiotherapy followed by sintilimab plus donafenib for hepatocellular carcinoma with portal vein tumor thrombus
ChiCTR2100051537Phase 2Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and donafenib in hepatocellular carcinoma (HCC), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Maximum tolerated dose and Progression-free survival. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
sintilimabdonafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100051537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051537.